Bradley J . Monk

Department

Obstetrics & Gynecology (Phoenix)

Position

Professor

Publications

• International journal of gynecological cancer
  Richardson Debra, etal RINATABART SESUTECAN MONOTHERAPY IN PATIENTS WITH ADVANCED ENDOMETRIAL CANCER: PART F OF THE PHASE 1/2 RAINFOL™-01 STUDY
  35:11, p. 102612 2025
• International journal of gynecological cancer
  Nicum Shibani, etal GOG-3119/ENGOT-EN29/TROFUSE-033: A PHASE 3, RANDOMIZED STUDY OF SACITUZUMAB TIRUMOTECAN PLUS PEMBROLIZUMAB VS PEMBROLIZUMAB ALONE AS FIRST-LINE MAINTENANCE THERAPY FOR MISMATCH REPAIR-PROFICIENT ENDOMETRIAL CANCER
  35:11, p. 102611 2025
• International journal of gynecological cancer
  Lorusso Domenica, etal SAFETY OF RUCAPARIB MONOTHERAPY IN ADVANCED HIGH-GRADE OVARIAN CANCER CLINICAL TRIALS
  35:11, p. 102262 2025
• International journal of gynecological cancer
  Hasegawa Kosei, etal PEMBROLIZUMAB PLUS CHEMOTHERAPY WITH OR WITHOUT BEVACIZUMAB IN PARTICIPANTS WITH PERSISTENT, RECURRENT, OR METASTATIC CERVICAL CANCER: 5-YEAR FOLLOW-UP RESULTS FROM KEYNOTE-826
  35:11, p. 102156 2025
• International journal of gynecological cancer
  Secord Angeles Alvarez, etal PREDICTIVE BLOOD-BASED BIOMARKERS IN CERVICAL CANCER PATIENTS TREATED WITH PACLITAXEL-BASED CHEMOTHERAPY WITH OR WITHOUT BEVACIZUMAB: RESULTS FROM GOG-0240
  35:11, p. 102158 2025
• International journal of gynecological cancer
  Lee Elizabeth, etal PART C OF RAINFOL™-01: A PHASE 1/2 STUDY OF SINGLE-AGENT RINATABART SESUTECAN IN PATIENTS WITH ADVANCED AND/OR METASTATIC PLATINUM-RESISTANT OVARIAN CANCER
  35:11, p. 102616 2025
• International journal of gynecological cancer
  Eskander Ramez N., etal REAL-WORLD TREATMENT PATTERNS OF PATIENTS WITH ADVANCED PLATINUM-RESISTANT AND PLATINUM-SENSITIVE OVARIAN CANCER WITHIN THE UNITED STATES: AN ANALYSIS OF SECONDARY DATA
  35:11, p. 102488 2025
• International journal of gynecological cancer
  Salani Ritu, etal TROFUSE-020/GOG-3101/ENGOT-CX20: A PHASE 3, RANDOMIZED, ACTIVE-CONTROLLED, OPEN-LABEL, MULTICENTER STUDY COMPARING SACITUZUMAB TIRUMOTECAN MONOTHERAPY VS TREATMENT OF PHYSICIAN’S CHOICE AS SECOND-LINE TREATMENT FOR RECURRENT/METASTATIC CERVICAL CANCER
  35:11, p. 102609 2025
• International journal of gynecological cancer
  Vergote Ignace, etal ENGOT-EN20/GOG-3083/XPORT-EC-042 A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, MULTICENTER TRIAL OF SELINEXOR IN MAINTENANCE THERAPY FOR PATIENTS WITH P53 WILD-TYPE, ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA
  35:11, p. 102472 2025
• Gynecologic oncology
  Chase Dana M, etal Patient-reported outcomes of a randomized phase III clinical trial of adjuvant radiation versus chemoradiation in intermediate risk, stage I/IIA cervical cancer patients treated with initial radical hysterectomy and pelvic lymphadenectomy (NRG/GOG-0263)
  202, p. 102 - 109 2025
• Journal of clinical oncology
  Monk Bradley J, etal Decoding the End Points of Poly (ADP-ribose) Polymerase Inhibitor Trials in Ovarian Cancer, p. JCO2501721 2025
• Molecular cancer therapeutics
  Leary Alexandra, etal Abstract B013: Cyclin E1 Positive Protein Status is a Predictive Biomarker of Azenosertib Benefit in Platinum-Resistant Ovarian Cancer: Part 2 of the DENALI Study (GOG-3066)
  24:10_Supplement, p. B013 - B013 2025
• Annals of oncology
  Kristeleit R S, etal Rucaparib maintenance for newly diagnosed advanced ovarian cancer: interim overall survival, progression-free survival, and safety at 5 years of follow-up from the phase III ATHENA-MONO/GOG-3020/ENGOT-ov45 study 2025
• Journal of clinical oncology
  Banerjee Susana N, etal Erratum: Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201, p. JCO2502377 2025
• Obstetrical & gynecological survey
  Olawaiye Alexander B., etal Relacorilant and Nab-Paclitaxel in Patients With Platinum-Resistant Ovarian Cancer (ROSELLA): An Open-label, Randomized, Controlled, Phase 3 Trial
  80:10, p. 636 - 638 2025
• Annals of oncology
  Ryu S Y, etal Randomized Phase III Trial of Adjuvant Radiation versus Chemoradiation in Intermediate-Risk, Early-stage Cervical Cancer following Radical Hysterectomy and Lymphadenectomy: Results from NRG Oncology/GOG-263/KGOG1008 2025
• Konstantinopoulos Panagiotis A, etal Primary Analysis of EPIK-O/ENGOT-ov61:Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without BRCA Mutation 2025
• Annals of oncology
  Mercieca-Bebber R., etal 1172P The relationship between patient-reported outcomes and clinician-rated toxicity in participants with locally advanced cervix cancer in the OUTBACK trial
  36, p. S772 - S773 2025
• Annals of oncology
  Monk B.J., etal 1166P Tisotumab vedotin plus carboplatin or pembrolizumab in recurrent or metastatic cervical cancer: 5-year results from the innovaTV 205/GOG-3024/ENGOT-cx8 study
  36, p. S769 - S770 2025
• Gynecologic oncology
  Chase Dana, etal Patient-reported outcomes on a randomized phase III clinical trial of adjuvant radiation versus chemoradiation in intermediate-risk, stage I/IIA cervical cancer treated with initial radical hysterectomy and pelvic lymphadenectomy (NCT#01101451)
  200, p. 4 - 5 2025
• Gynecologic oncology
  Simpkins Fiona, etal Cyclin E1 as a predictive biomarker of azenosertib benefit in platinum-resistant ovarian cancer: Outcomes from part 1b of the DENALI study (GOG-3066)
  200, p. 8 - 9 2025
• Gynecologic oncology
  Ryu Sang Young, etal Randomized phase III trial of adjuvant radiation versus chemoradiation in intermediate-risk, early-stage cervical carcinoma following radical hysterectomy and lymphadenectomy: Results of NRG oncology/GOG-263
  200, p. 4 2025
• Gynecologic oncology
  Grisham Rachel, etal ENCORE: Avutometinib plus defactinib in recurrent low-grade serous ovarian cancer (ENGOT-OV60/GOG-3052/RAMP 201): Dose intensity and subgroup analysis
  200, p. 34 - 35 2025
• Cancer treatment and research communications
  Monk Bradley J., etal DEVELOPMENT OF ANTI-CANCER MEDICINES IN THE CURRENT ERA, p. 101002 - 101002 2025
• Gynecologic oncology
  Levin Gabriel, etal Racial and ethnic enrollment disparities in clinical trials leading to drug approvals for gynecologic malignancies by the Food and Drug Administration
  200, p. 150 2025
• Gynecologic oncology
  File Brittany, etal Trends in FDA approval of novel therapies in women's cancer: A study of the last 25 years
  200, p. 114 - 115 2025
• Gynecologic oncology
  Richardson Michael, etal Gynecologic cancers in tumor-agnostic trials: Keys to regulatory approval
  200, p. 74 2025
• Gynecologic oncology
  Lee Elizabeth, etal Part C of a phase I/II study evaluating single agent rinatabart sesutecan in patients with advanced and/or metastatic platinum-resistant ovarian cancer
  200, p. 112 - 113 2025
• Gynecologic oncology
  Bujnak Alyssa, etal Predictive biomarkers for chemotherapy plus bevacizumab in recurrent/metastatic cervical cancer: The NRG Oncology/GOG-0240 National Institutes of Health Cancer Moonshot
  200, p. 352 - 353 2025
• Gynecologic oncology
  Lee Jung-Yun, etal Efficacy and safety of luveltamab tazevibulin in patients with recurrent platinum-resistant ovarian cancer: Results from the dose-optimization stage of the REFRαME-O1 (GOG-3086, ENGOT-79ov, and APGOT-OV9) phase II/III study
  200, p. 351 2025
• Gynecologic oncology
  Salani Ritu, etal TroFuse-020/GOG-3101/ENGOT-cx20: A phase III, randomized, active-controlled, open-label, multicenter study comparing sacituzumab tirumotecan monotherapy versus treatment of physician's choice as second-line treatment for recurrent or metastatic cervical c
  200, p. 121 - 122 2025
• International journal of gynecological cancer
  Podder Vivek, etal Checkpoint Inhibitor Rechallenge in Advanced Endometrial Cancer: Revisiting the Immune Landscape Beyond First-Line Therapy, p. 102124 2025
• Journal of clinical oncology
  Konstantinopoulos Panagiotis A, etal Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without BRCA Mutation, p. JCO2500225 2025
• Journal of clinical oncology
  Banerjee Susana N, etal Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201, p. JCO2500112 2025
• Gynecologic oncology
  Chan John K., etal Optimizing therapy for cervical cancers – Translating trial data into clinical decision-making
  199, p. 47 - 50 2025
• Annals of oncology
  Mayadev J, etal Ultrasensitive detection and tracking of circulating tumor DNA to predict relapse and survival in patients with locally advanced cervical cancer: phase III CALLA trial analyses 2025
• The Lancet (British edition)
  Olawaiye Alexander B, etal Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial 2025
• International journal of gynecological cancer
  Lightfoot Michelle DS, etal Oral Mucositis Associated with Antibody-Drug Conjugates in Gynecologic Oncology: Strategies for Prevention and Treatment, p. 101997 2025
• Journal of clinical oncology
  Bujnak Alyssa, etal miRNA(s) expression as predictive biomarkers in recurrent/metastatic cervical cancer: The NRG Oncology/GOG-0240 NIH Cancer Moonshot
  43:16_suppl, p. 5523 - 5523 2025
• International journal of gynecological cancer
  Secord Angeles Alvarez, etal Expanding the workforce of clinical trial investigators committed to gynecologic cancer research: The GOG Foundation, Inc.’s Scholar Career Development Award and New Investigator Program, p. 101982 2025
• Journal of clinical oncology
  Shahin Mark S., etal Impact of disease progression on health-related quality of life (HRQOL): Updated results from the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line (1L) maintenance therapy in patients with newly diagnosed advanced ovarian cancer (aOC)
  43:16_suppl, p. 5551 - 5551 2025
• Journal of clinical oncology
  Mayadev Jyoti, etal Ultrasensitive detection and tracking of circulating tumor DNA (ctDNA) and association with relapse and survival in locally advanced cervical cancer (LACC): Phase 3 CALLA trial analyses
  43:16_suppl, p. 5502 - 5502 2025
• Journal of clinical oncology
  Salani Ritu, etal TroFuse-020/GOG-3101/ENGOT-cx20: A phase 3, randomized, active-controlled, open-label, multicenter study comparing sacituzumab tirumotecan monotherapy vs treatment of physician’s choice as second-line treatment for recurrent or metastatic cervical cancer
  43:16_suppl 2025
• Journal of clinical oncology
  Mercieca-Bebber Rebecca, etal Patient-reported outcomes (PROs) in locally advanced cervical cancer (LACC): Insights from the OUTBACK trial
  43:16_suppl, p. 5503 - 5503 2025
• ESMO open
  Oaknin A., etal 75MO Efficacy and safety of rucaparib maintenance treatment in patients from ATHENA-MONO/GOG-3020/ENGOT-ov45 with newly diagnosed advanced ovarian cancer not associated with homologous recombination deficiency
  10 2025
• ESMO open
  Okines A., etal 304MO Tucatinib and trastuzumab for previously treated HER2-mut MBC: Final analysis of a phase II basket study (SGNTUC-019)
  10, p. 104876 2025
• International journal of gynecological cancer
  Podder Vivek, etal Repurposing FDA-Approved Cancer Therapies: Exploring Endocrine and Targeted Pathways in Low-Grade Serous Ovarian Cancer Treatment, p. 101938 2025
• Cancer treatment reviews
  Monk Bradley J., etal Optimal bevacizumab treatment strategy in advanced ovarian cancer: A review, p. 102945 2025
• Gynecologic oncology
  Matulonis Ursula A., etal ENGOT-OV16/NOVA trial of niraparib in recurrent ovarian cancer: Survival and long-term safety
  195, p. 192 2025
• Gynecologic oncology
  Leath, 3rd Charles A, etal Incorporation of triapine (T) to cisplatin chemoradiation (CRT) for locally advanced cervical and vaginal cancer: Results from NRG-GY006, a phase III randomized trial
  195, p. 122 - 133 2025
• Gynecologic oncology
  Carter Jeanne, etal Evaluation of physical function and quality of life before and after nonradical surgical therapy for stage IA1 and IA2-IB1 cervical cancer (GOG-0278)
  195, p. 50 2025
• Gynecologic oncology
  Covens Allan, etal Evaluation of efficacy and fertility after nonradical surgical therapy (extra fascial hysterectomy or cone biopsy, with pelvic lymphadenectomy) for stage IA1, IA2, and IB1 cervical cancer (GOG-0278)
  195, p. 59 2025
• International journal of gynecological cancer
  Leitao Mario M., etal ROCC/GOG-3043: A randomized controlled trial of robotic versus open surgery for early-stage cervical cancer, p. 101760 2025
• International journal of gynecological cancer
  Salani Ritu, etal TroFuse-020/GOG-3101/ENGOT-Cx20: A Phase 3, Randomised, Active-Controlled, Open-Label, Multicentre Study Comparing Sacituzumab Tirumotecan Monotherapy Vs Treatment Of Physician’s Choice As Second-Line Treatment For Recurrent Or Metastatic Cervical Cancer
  35:2, p. 100497 2025
• International journal of gynecological cancer
  Ghamande Sharad, etal ATHENA-MONO Post-Progression Survival Data Update In Patients With Newly Diagnosed Advanced Ovarian Cancer
  35:2, p. 100319 2025
• International journal of gynecological cancer
  Lokich Elizabeth, etal Time Course Of Adverse Events In Primary Advanced Or Recurrent Endometrial Cancer Treated With Dostarlimab Plus Chemotherapy In The ENGOT-EN-6-NSGO/GOG-3031/RUBY Trial
  35:2, p. 101722 2025
• European journal of cancer (1990)
  Vergote Ignace, etal Tumor Treating Fields therapy in platinum-resistant ovarian cancer: Results of the ENGOT-ov50/GOG-3029/INNOVATE-3 pivotal phase 3 randomized study, p. 115306 2025
• International journal of gynecological cancer
  Lorusso Domenica, etal Updated Patient-Reported Outcomes In The PRIMA/ENGOT-OV26/GOG-3012 Trial Of Niraparib First-Line Maintenance Therapy In Patients With Newly Diagnosed Advanced Ovarian Cancer
  35:2, p. 100093 2025
• Gynecologic oncology
  Bogani Giorgio, etal Incorporating immune checkpoint inhibitors in epithelial ovarian cancer
  193, p. 30 - 40 2025
• American journal of obstetrics and gynecology
  Levin Gabriel, etal Racial and ethnic enrollment disparities in clinical trials leading to FDA approvals for gynecologic malignancies, p. - 2025
• Nature medicine
  Okines Alicia F C, etal Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer: a phase 2 basket trial 2025
• European journal of cancer (1990)
  Oaknin Ana, etal Cemiplimab in recurrent cervical cancer: Final analysis of overall survival in the phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial
  216, p. 115146 2025
• Nature reviews. Clinical oncology
  Francoeur Alex A, etal Treatment advances across the cervical cancer spectrum 2025
• Therapeutic advances in medical oncology
  Powell Matthew A, etal A plain language summary publication of patients' survival with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel
  17, p. 17588359251342241 2025
• Journal of gynecologic oncology
  Kim Yong-Man, etal Pembrolizumab plus chemotherapy with or without bevacizumab in East Asian participants with persistent, recurrent, or metastatic cervical cancer: results from KEYNOTE-826 final analysis
  36 2025
• Mirza Mansoor R, etal A Plain Language Summary of “Dostarlimab for primary advanced or recurrent endometrial cancer” 2025
• Journal of comparative effectiveness research
  Graybill Whitney S, etal Use of individualized starting dose and niraparib hematologic adverse event management costs in ovarian cancer
  14:1, p. e240133 2025
• J Comp Eff Res
  Graybill Whitney S, etal Use of individualized starting dose and niraparib hematologic adverse event management costs in ovarian cancer
  14:1, p. e240133 2025
• Annals of oncology
  González-Martín A, etal Reply to Letter to the Editor 'Long-term outcomes in the PRIMA trial: a closer look at PFS and OS' by Wu et al 2024
• Cancer research communications
  Zhang Hailei, etal Potential synergistic effect between niraparib and statins in ovarian cancer clinical trials 2024
• Cancer Res Commun
  Zhang Hailei, etal Potential synergistic effect between niraparib and statins in ovarian cancer clinical trials 2024
• Oncology and therapy
  Monk Bradley J., etal Cost-Effectiveness of Pembrolizumab as First-Line Treatment in Patients with Persistent, Recurrent, or Metastatic Cervical Cancer in the United States 2024
• Gynecologic oncology
  Grisham Rachel, etal A phase III, randomized trial evaluating avutometinib plus defactinib compared with investigator's choice of therapy among patients with recurrent low-grade serous ovarian cancer: GOG-3097/ENGOT-OV81/NCRI/RAMP 301
  190, p. S282 - S283 2024
• Gynecologic oncology
  Banerjee Susana, etal Avutometinib plus defactinib in recurrent low-grade serous ovarian cancer: A subgroup analysis of ENGOT-OV60/GOG-3052/RAMP 201 Part A
  190, p. S55 - S56 2024
• Gynecologic oncology
  Moore Kathleen, etal GOG-3084: A phase II trial of ADP-A2M4CD8 TCR-T cell therapy, alone or in combination with nivolumab, among patients with recurrent ovarian cancers
  190, p. S281 - S282 2024
• Gynecologic oncology
  Graybill Whitney, etal Use of individualized starting dose and niraparib hematologic adverse event management costs in ovarian cancer
  190, p. S274 - S275 2024
• Gynecologic oncology
  Pothuri Bhavana, etal Examining health-related quality of life outcomes among older patients with advanced ovarian cancer treated with niraparib first-line maintenance therapy in context with efficacy and safety findings: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial
  190, p. S295 - S296 2024
• Gynecologic oncology
  Hunsberger Kyra, etal Standard of care treatment for stage IVB cervical cancer: A systematic review and meta-analysis
  190, p. S421 - S421 2024
• Gynecologic oncology
  Kristeleit Rebecca, etal Interim post-progression data and updated survival in patients with newly diagnosed advanced ovarian cancer in ATHENA-MONO
  190, p. S10 - S11 2024
• Gynecologic oncology
  Banerjee Susana, etal A phase Ib, multicenter, open-label study of NXP800, a novel GCN2 kinase activator, among patients with platinum-resistant, ARID1A-mutated ovarian cancer (ENGOT-GYN5/NCRI/NXP800-101; GOG-3087)
  190, p. S302 - S302 2024
• Annals of oncology
  Lorusso D, etal Pembrolizumab Plus Chemotherapy for Advanced and Recurrent Cervical Cancer: Final Analysis According to Bevacizumab Use in the Randomized KEYNOTE-826 Study 2024
• International journal of gynecological cancer
  Barlin Joyce, etal LB010/#1590  A phase 2 randomized dose optimization trial of gotistobart, a PH-sensitive anti-CTLA-4, in combination with pembrolizumab in platinum-resistant ovarian cancer (PROC, preserve-004/GOG-3081; NCT05446298)
  34, p. A6 - A8 2024
• International journal of gynecological cancer
  Lorusso Domenica, etal TP003/#1538  Phase 3 ENGOT-en23/GOG-3095/MK-2870–005 study: sacituzumab tirumotecan (Sac-TMT) monotherapy vs treatment of physician’s choice chemotherapy in patients with endometrial cancer who received prior chemotherapy and immunotherapy
  34, p. A348 - A348 2024
• International journal of gynecological cancer
  Grisham Rachel, etal PR029/#943  A phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator’s choice of therapy in patients with recurrent low-grade serous ovarian cancer: GOG-3097/ENGOT-ov81/NCRI/RAMP 301
  34, p. A53 - A54 2024
• International journal of gynecological cancer
  Bixel Kristin, etal TP001/#1584  GOG-3043 (nct04831580): a randomized non-inferiority trial of robotic versus open surgery for early stage cervical cancer (ROCC)
  34, p. A347 - A347 2024
• International journal of gynecological cancer
  Oaknin Ana, etal TP010/#1537  Efficacy and safety of luveltamab tazevibulin in patients with recurrent platinum-resistant ovarian cancer: the reframe-01 (GOG-3086, ENGOT-79ov, and APGOT-OV9) phase 2/3 study
  34, p. A351 - A351 2024
• International journal of gynecological cancer
  Banerjee Susana, etal LB007/#1548  Efficacy and safety of avutometinib ± defactinib in recurrent low grade serous ovarian cancer: primary analysis of ENGOT-OV60/GOG-3052/RAMP 201
  34, p. A13 - A13 2024
• European journal of cancer (1990)
  Nakamura Y., etal 3 Oral: Tucatinib and Trastuzumab for Patients With Previously Treated, HER2- Altered Solid Tumors (SGNTUC-019): A Phase 2 Basket Study
  211, p. 114532 2024
• Annals of oncology
  Monk B.J., etal Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial 2024
• International journal of gynecological cancer
  Vergote Ignace, etal ENGOT-EN20/GOG-3083/XPORT-EC-042 - A phase III, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma: ratio
  34:8, p. 1283 2024
• Gynecologic oncology
  Pothuri Bhavana, etal Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial
  184, p. 168 - 177 2024
• Gynecologic oncology reports
  Rimel Bobbie J., etal Cytochrome P450 inhibitor/inducer treatment patterns among patients in the United States with advanced ovarian cancer who were prescribed or were eligible for poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitors in the first-line maintenance set, p. 101332 2024
• Chan John, etal Preoperative and pre-chemotherapy CA-125 levels in high-risk early-stage ovarian cancer - An NRG/GOG study 2024
• Gynecologic oncology
  Valabrega Giorgio, etal Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial 2024
• Gynecologic oncology
  Chase Dana M., etal Impact of disease progression on health-related quality of life of advanced ovarian cancer patients - Pooled analysis from the PRIMA trial
  166:3, p. 494 - 502 2022
• International journal of gynecological cancer
  Freyer G, etal 17 Safety and patient-reported outcomes in patients receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial
  30:Suppl 3, p. A12 - A13 2020
• International journal of gynecological cancer
  Chase Dana, etal Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study
  30:5, p. 596 - 601 2020
• Critical Reviews in Oncology/Hematology
  Monk Bradley J., etal Antiangiogenic agents as a maintenance strategy for advanced epithelial ovarian cancer
  86:2, p. 161 - 175 2013
• European Journal of Gynaecological Oncology
  Jordan S. M., etal High pathologic misdiagnosis of cervical adenocarcinoma in situ
  34:5, p. 446 - 449 2013
• Gynecologic oncology
  Osann Kathryn, etal Recruitment and retention results for a population-based cervical cancer biobehavioral clinical trial
  121:3, p. 558 - 564 2011